Search Results - "von der Assen, A."

8p deletion is strongly linked to poor prognosis in breast cancer by Lebok, P, Mittenzwei, A, Kluth, M, Özden, C, Taskin, B, Hussein, K, Möller, K, Hartmann, A, Lebeau, A, Witzel, I, Mahner, S, Wölber, L, Jänicke, F, Geist, S, Paluchowski, P, Wilke, C, Heilenkötter, U, Simon, R, Sauter, G, Terracciano, L, Krech, R, von der Assen, A, Müller, V, Burandt, E

“…Deletions of chromosome 8p occur frequently in breast cancers, but analyses of its clinical relevance have been limited to small patient cohorts and provided…”
Get full text

5201 POSTER The EXpand Study – Effect of Zoledronic Acid on Prevention of Bone Loss, During Extended Adjuvant Therapy With Letrozole in Postmenopausal Women With Primary Hormone Receptor Positive Breast Cancer Compared to Letrozole Alone by Hellrieqel, M, Mueller, M, Reimer, T, Baerens, D.T, von der Assen, A, Hackmann, J, Schmidt, K, Baier-Ebert, M, Spall, T, Emons, G

Get full text

Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial by Möbus, V., Jackisch, C., Lück, H.J., du Bois, A., Thomssen, C., Kuhn, W., Nitz, U., Schneeweiss, A., Huober, J., Harbeck, N., von Minckwitz, G., Runnebaum, I.B., Hinke, A., Konecny, G.E., Untch, M., Kurbacher, C.

“…Primary breast cancer (BC) patients with extensive axillary lymph-node involvement have a limited prognosis. The Arbeitsgemeinschaft fuer Gynaekologische…”
Get full text

Abstract P5-20-09: Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study by Möbus, V, Mahlberg, R, Janni, W, Tomé, O, Marmé, F, Forstbauer, H, Reimer, T, von der Assen, A, Reinisch, M, Lorenz, R, Schmatloch, S, Schmidt, M, Sinn, B, Klutinus, N, Stickeler, E, Untch, M, Seiler, S, Burchardi, N, von Minckwitz, G, Loibl, S

“…Background A new subcutaneous (s.c.) formulation of trastuzumab became available in 2013 based on equivalent efficacy, pharmacokinetic (PK) profile and safety…”
Get full text

Abstract P5-21-02: Hormone receptor status and endocrine therapy in a prospective observation study on trastuzumab (Herceptin®) in the adjuvant treatment of breast cancer by Dall, P, Friedrichs, K, Petersen, V, Hinke, A, Brucker, C, Schmidt, P, von der Assen, A, Jungberg, P, Bohnsteen, B

“…Background: Based on the findings from large randomized studies, Trastuzumab (T) was registered in 2006 for the treatment of early stage, HER2+ breast cancer…”
Get full text

Gene Expression Profiling for Therapy Prediction in a Breast Cancer Neoadjuvant Therapy Study Applying Docetaxel/Epirubicin/Cyclophosphamide by Kemming, D., Schlotter, C., Bosse, U., Vogt, U., Muhs, H., von der Assen, A., Brandt, B.

“…Background: Gene expression profiling is a powerful tool to identify markers associated with clinical and therapy outcome of cancer patients. Prediction of the…”
Get full text

Oncotype DX® und Proliferationsänderung durch kurzzeitige präoperative endokrine Induktionstherapie zur Therapieentscheidung beim frühen Mammakarzinom: Biomarkerdaten aus der prospektiven multi-zentrischen Phase II/III WSG-ADAPT Studie by Krauß, K, Gluz, O, Kümmel, S, Schumann, R von, Nuding, B, Schumacher, C, Maass, N, Rezai, M, Braun, M, Aktas, B, Forstbauer, H, Kusche, M, Krämer, S, der Assen, A von, Kreipe, H, Christgen, M, Hofmann, D, Kates, R, Shak, S, Würstlein, R, Nitz, U, Harbeck, N

“…Abstract only…”
Get full text

Oncotype DX® und Proliferationsänderung durch kurzzeitige präoperative endokrine Induktionstherapie zur Therapieentscheidung beim frühen Mammakarzinom: Biomarkerdaten aus der prospektiven multi-zentrischen Phase II/III WSG-ADAPT Studie by Krauß, K, Gluz, O, Kümmel, S, Schumann, R von, Nuding, B, Schumacher, C, Maass, N, Rezai, M, Braun, M, Aktas, B, Forstbauer, H, Kusche, M, Krämer, S, der Assen, A von, Kreipe, H, Christgen, M, Hofmann, D, Kates, R, Shak, S, Würstlein, R, Nitz, U, Harbeck, N

“…Zielsetzung: Die WSG-ADAPT Studie optimiert adjuvante Therapie bei HR+/HER2- Mammakarzinompatientinnen mit mittlerem Rezidivrisiko. Individuelle endokrine…”
Get full text

Mammareduktionsplastik mit zentralem Drüsentiel, eine neue Methode by Brunnert, K., von der Assen, A., Herkenhoff, S.

Get full text